Co-Authors
This is a "connection" page, showing publications co-authored by John McCoy and Carlos Wambier.
Connection Strength
3.810
-
Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial. Front Med (Lausanne). 2021; 8:668698.
Score: 0.957
-
Androgen sensitivity gateway to COVID-19 disease severity. Drug Dev Res. 2020 11; 81(7):771-776.
Score: 0.882
-
Androgenetic alopecia may be associated with weaker COVID-19 T-cell immune response: An insight into a potential COVID-19 vaccine booster. Med Hypotheses. 2021 01; 146:110439.
Score: 0.229
-
5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia. J Eur Acad Dermatol Venereol. 2021 Apr; 35(4):e243-e246.
Score: 0.229
-
Clinical symptoms of hyperandrogenic women diagnosed with COVID-19. J Eur Acad Dermatol Venereol. 2021 Feb; 35(2):e101-e104.
Score: 0.228
-
Androgen receptor genetic variant predicts COVID-19 disease severity: a prospective longitudinal study of hospitalized COVID-19 male patients. J Eur Acad Dermatol Venereol. 2021 Jan; 35(1):e15-e17.
Score: 0.227
-
Male balding as a major risk factor for severe COVID-19: A possible role for targeting androgens and transmembrane protease serine 2 to protect vulnerable individuals. J Am Acad Dermatol. 2020 12; 83(6):e401-e402.
Score: 0.226
-
Androgenetic alopecia in COVID-19: Compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign. J Am Acad Dermatol. 2020 12; 83(6):e453-e454.
Score: 0.224
-
Racial variations in COVID-19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti-androgens a potential treatment for COVID-19? J Cosmet Dermatol. 2020 Jul; 19(7):1542-1543.
Score: 0.222
-
Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The "Gabrin sign". J Am Acad Dermatol. 2020 Aug; 83(2):680-682.
Score: 0.221
-
Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men. J Eur Acad Dermatol Venereol. 2021 Jan; 35(1):e13-e15.
Score: 0.057
-
A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain - A potential clue to the role of androgens in COVID-19 severity. J Cosmet Dermatol. 2020 Jul; 19(7):1545-1547.
Score: 0.055
-
What does androgenetic alopecia have to do with COVID-19? An insight into a potential new therapy. Dermatol Ther. 2020 Jul; 33(4):e13365.
Score: 0.055